Contents
By accessing or using this website (the "Site"), you agree to be bound by these Terms of Service ("Terms"), our Privacy Policy, and all applicable laws and regulations. If you do not agree with any of these Terms, you must discontinue use of this Site immediately.
These Terms constitute a legally binding agreement between you and Hajik Holdings LLC, a Delaware limited liability company with a registered address at 16192 Coastal Highway, Lewes, Delaware 19958. "We," "us," and "our" refer to Hajik Holdings LLC, the operator of this Site. "You" and "your" refer to you, the user.
This Site is operated by Hajik Holdings LLC as an independent advertising and marketing website. We are not MEDVi. We are not a healthcare provider, medical practice, pharmacy, or telehealth platform. We do not prescribe medications, provide medical consultations, dispense pharmaceuticals, or make clinical decisions of any kind.
This Site publishes promotional and informational content about telehealth weight management programs, specifically the MEDVi program. All content on this Site is advertising content and should be understood as such.
In compliance with the Federal Trade Commission's Guides Concerning the Use of Endorsements and Testimonials in Advertising, we disclose the following:
We encourage you to independently evaluate any telehealth program before enrolling and to consult your own healthcare provider regarding any treatment decisions.
All content on this Site — including articles, questionnaires, quiz results, educational material, FAQs, and any other information — is provided for informational and promotional purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment.
Always seek the advice of your own physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this Site.
If you are experiencing a medical emergency, call 911 (or your local emergency number) immediately.
Weight management involves complex medical, metabolic, behavioral, and genetic factors. Any decision to pursue pharmacological weight management should be made in consultation with a licensed healthcare provider who has evaluated your individual health profile, medical history, current medications, and risk factors.
GLP-1 receptor agonist medications carry potential side effects including, but not limited to:
Serious side effects, though less common, may include pancreatitis, gallbladder problems, kidney problems, allergic reactions, changes in vision (in patients with diabetes), and increased heart rate. GLP-1 medications may interact with other medications including insulin and sulfonylureas.
GLP-1 medications are contraindicated in certain populations and medical conditions. A physician must evaluate whether any GLP-1 medication is appropriate for your individual situation. This Site does not and cannot make that determination.
Weight loss outcomes depend on many factors including, but not limited to: genetics, starting weight, metabolic health, age, adherence to prescribed protocols, lifestyle modifications (diet and exercise), concurrent medical conditions, and other individual variables.
Clinical trial data cited in general media coverage of GLP-1 medications was generated using FDA-approved brand-name formulations (such as Ozempic® and Mounjaro®) under controlled research conditions. These results may not be representative of outcomes achievable with compounded formulations, in non-research settings, or for any specific individual.
Any statistics, study references, or outcome descriptions on this Site refer to published research on FDA-approved brand-name products unless explicitly stated otherwise. They are included for informational context only and do not predict, promise, or guarantee any individual result.
GLP-1 medications are intended to be used as part of a comprehensive approach that includes improved nutrition and increased physical activity. Medication alone, without lifestyle modification, may not produce meaningful results.
The MEDVi program referenced on this Site utilizes compounded formulations of semaglutide and/or tirzepatide. These compounded medications are important to distinguish from brand-name FDA-approved products:
Compounded medications are prepared by licensed compounding pharmacies using the active pharmaceutical ingredient (semaglutide or tirzepatide). They are customized preparations, not manufactured by the brand-name pharmaceutical companies (Novo Nordisk or Eli Lilly).
Compounded semaglutide and compounded tirzepatide have not been approved by the U.S. Food and Drug Administration (FDA). They have not undergone the FDA's drug approval process for safety, efficacy, or quality. They have not been tested for bioequivalence to FDA-approved brand-name formulations.
Clinical trials and published research commonly cited in media coverage of GLP-1 medications (including studies referenced on this Site) were conducted using FDA-approved brand-name formulations such as Ozempic® (semaglutide, manufactured by Novo Nordisk) and Mounjaro® (tirzepatide, manufactured by Eli Lilly). These clinical results may not be directly applicable to compounded formulations.
Compounding pharmacies that prepare these medications operate under state pharmacy board oversight and, in some cases, under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This regulatory framework is distinct from the FDA drug approval process that governs brand-name pharmaceuticals.
Ozempic® is a registered trademark of Novo Nordisk A/S. Mounjaro® is a registered trademark of Eli Lilly and Company. Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound® is a registered trademark of Eli Lilly and Company. These trademarks are referenced on this Site for informational and comparative purposes only and do not imply endorsement, sponsorship, or affiliation with MEDVi or with us.
"$179/month," where referenced on this Site, reflects the lowest available starting price during the initial titration phase of compounded semaglutide through the MEDVi program. This figure is subject to the following qualifications:
This Site may include a quiz or questionnaire designed to help you determine whether the MEDVi program may be relevant to your situation. This quiz is important to understand in context:
This Site contains links to third-party websites, including MEDVi's platform. When you click a link to a third-party site, you leave this Site and become subject to that third party's terms of service and privacy policy.
We do not control, endorse, or assume responsibility for the content, privacy practices, products, or services of any third-party website. The inclusion of a link does not imply our endorsement of the linked site (beyond our disclosed affiliate relationship with MEDVi).
We are not responsible for any transactions, interactions, or disputes between you and MEDVi or any other third party. Your relationship with MEDVi, including any medical consultations, prescriptions, or financial transactions, is governed by MEDVi's own terms and policies.
All content on this Site — including text, graphics, logos, layouts, design elements, and code — is owned by us or licensed to us and is protected by applicable copyright, trademark, and intellectual property laws. You may not reproduce, distribute, modify, or create derivative works from any content on this Site without our prior written consent.
Third-party trademarks referenced on this Site (including Ozempic®, Mounjaro®, Wegovy®, Zepbound®, Novo Nordisk, and Eli Lilly) are the property of their respective owners and are used solely for informational reference.
You agree not to use this Site for any unlawful purpose or in any way that could damage, disable, or impair the Site. Prohibited uses include, but are not limited to:
We collect certain personal and non-personal information when you use this Site, including quiz responses, browsing data, and information collected through cookies and tracking pixels. Our data collection and use practices are described in detail in our Privacy Policy.
Key points:
By using this Site, you acknowledge that you have read and understood our Privacy Policy.
THIS SITE AND ALL CONTENT, MATERIALS, INFORMATION, AND SERVICES PROVIDED ON OR THROUGH THIS SITE ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED.
TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, WE DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, AND ACCURACY.
We do not warrant that: the Site will be uninterrupted, error-free, or secure; any information on the Site is complete, accurate, or current; or that the Site will meet your specific requirements or expectations. Content on this Site may contain errors, inaccuracies, or omissions.
TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, WE SHALL NOT BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, OR ANY LOSS OF PROFITS, REVENUE, DATA, OR GOODWILL, ARISING OUT OF OR RELATED TO YOUR USE OF THIS SITE OR ANY CONTENT, PRODUCTS, OR SERVICES REFERENCED HEREIN, REGARDLESS OF THE THEORY OF LIABILITY.
OUR TOTAL AGGREGATE LIABILITY FOR ALL CLAIMS ARISING OUT OF OR RELATED TO THESE TERMS OR YOUR USE OF THIS SITE SHALL NOT EXCEED ONE HUNDRED DOLLARS ($100.00).
WE ARE NOT LIABLE FOR ANY ACTIONS, DECISIONS, OR OUTCOMES RELATED TO YOUR INTERACTION WITH MEDVi, ANY PHYSICIAN, OR ANY MEDICATION. YOUR MEDICAL DECISIONS ARE YOUR OWN RESPONSIBILITY IN CONSULTATION WITH YOUR HEALTHCARE PROVIDER.
You agree to indemnify, defend, and hold harmless us, our affiliates, officers, directors, employees, and agents from and against any and all claims, liabilities, damages, losses, costs, and expenses (including reasonable attorneys' fees) arising out of or related to: your use of this Site; your violation of these Terms; your violation of any applicable law or regulation; or any information you submit through this Site.
These Terms shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of law provisions. Any dispute arising out of or relating to these Terms or your use of this Site shall be resolved exclusively in the state or federal courts located in Sussex County, Delaware, and you consent to the personal jurisdiction of such courts.
YOU AGREE THAT ANY CAUSE OF ACTION ARISING OUT OF OR RELATED TO THIS SITE MUST BE COMMENCED WITHIN ONE (1) YEAR AFTER THE CAUSE OF ACTION ACCRUES. OTHERWISE, SUCH CAUSE OF ACTION IS PERMANENTLY BARRED.
If any provision of these Terms is found to be invalid, illegal, or unenforceable by a court of competent jurisdiction, the remaining provisions shall continue in full force and effect. The invalid provision shall be modified to the minimum extent necessary to make it valid and enforceable while preserving the original intent.
We reserve the right to modify these Terms at any time. When we make material changes, we will update the "Last Updated" date at the top of this page. Your continued use of this Site after any changes constitutes your acceptance of the modified Terms. We encourage you to review these Terms periodically.
If you have questions about these Terms of Service, please contact us at:
Company: Hajik Holdings LLC
Email: [email protected]
Mailing Address: 16192 Coastal Highway, Lewes, Delaware 19958